4D Molecular Therapeutics Inc Ordinary Shares FDMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FDMT is a good fit for your portfolio.
News
-
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
-
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
-
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
-
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
-
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
Trading Information
- Previous Close Price
- $18.52
- Day Range
- $18.22–19.33
- 52-Week Range
- $9.44–36.25
- Bid/Ask
- $17.60 / $18.80
- Market Cap
- $948.76 Mil
- Volume/Avg
- 760,871 / 858,020
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 38.78
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 171
Comparables
Valuation
|
Metric
|
FDMT
|
INZY
|
DSGN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.56 | 3.03 | 1.10 |
Price/Sales | 38.78 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
FDMT
INZY
DSGN
Financial Strength
|
Metric
|
FDMT
|
INZY
|
DSGN
|
|---|---|---|---|
Quick Ratio | 32.06 | 13.39 | 38.39 |
Current Ratio | 32.65 | 14.05 | 38.61 |
Interest Coverage | — | — | — |
Quick Ratio
FDMT
INZY
DSGN
Profitability
|
Metric
|
FDMT
|
INZY
|
DSGN
|
|---|---|---|---|
Return on Assets (Normalized) | −21.50% | −40.22% | −15.23% |
Return on Equity (Normalized) | −23.26% | −56.07% | −15.89% |
Return on Invested Capital (Normalized) | −26.76% | −45.94% | −15.72% |
Return on Assets
FDMT
INZY
DSGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Jknbyfmtb | Njqzf | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kbpddwvk | Vcptwfv | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lbfnwrgc | Llzvrw | $118.7 Bil | |||
| Moderna Inc
MRNA
| Kxxgtwd | Ryf | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lcgyygxb | Hdjnk | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Bxqklhv | Stts | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Ylcgttsl | Jmtn | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gqqrtjdw | Rqtqqx | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Xnzxkrhsl | Nvxvh | $15.0 Bil | |||
| Incyte Corp
INCY
| Qyxylfwtx | Xcclyn | $13.5 Bil |